Date: 2013-06-20
Type of
information: Results
phase: preclinical
Announcement: results
Company: Protalix BioTherapeutics (Israel)
Product: PRX-110
Action
mechanism:
- protein/enzyme. PRX-110 is the Company's proprietary plant cell recombinant human Deoxyribonuclease 1 (DNase 1). PRX-110 works by cleaving extracellular DNA and thinning the thick mucus that accumulates in CF patients' lungs.
Disease: cystic fibrosis (CF)
Therapeutic
area: Rare diseases - Genetic diseases
Country:
Trial
details:
Latest
news:
- • On June 20, 2013, Protalix BioTherapeutics has held an Analyst Event in which included the disclosure of new data regarding new compounds in development. One of this compound PRX-110, is the company's proprietary plant cell recombinant human Deoxyribonuclease 1 (DNase 1) under development for the treatment of CF, to be administered by inhalation. PRX-110 works by cleaving extracellular DNA and thinning the thick mucus that accumulates in CF patients\' lungs. In preclinical trials, PRX-110 demonstrated improved enzyme kinetics, less sensitivity to inhibition by actin and improved ex-vivo efficacy when compared to Pulmozyme®, the only approved form of recombinant DNase 1 manufactured in Chinese hamster ovary (CHO) cells. The Company held a pre-Investigational New Drug (IND) meeting with the FDA in 2012, and plans to file an IND with the FDA following the completion of toxicology studies, which is expected to occur by year end.
Is
general: Yes
